Discover
CELZ
Creative Medical Technology Holdings, Inc.
1.27
8 x 1.24
1 x 1.30
bid
ask
-
0.18
12.41%
5 @ 07:10 AM
1.24 -0.03 (2.36%)
| Ytd | -35.20% | |
| 1y | -51.89% |
1.17
day range
1.37
0.79
52 week range
6.25
| Open | 1.36 | Prev Close | 1.45 | Low | 1.17 | High | 1.37 | Mkt Cap | 4.69M |
| Vol | 4.71M | Avg Vol | 3.22M | EPS | -2.07 | P/E | N/A | Forward P/E | -0.84 |
| Beta | 5.03 | Short Ratio | 0.56 | Inst. Own | 3.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.13 | 200-d Avg | 2.42 | 1yr Est | 30.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-08 | 2024-09 | -0.85 | -0.75 | 0.1 | 11.76% |
| 2024-08-09 | 2024-06 | -0.84 | -1.11 | -0.27 | -32.14% |
| 2024-08-09 | 2024-06 | -0.84 | N/A | N/A | N/A |
| 2024-05-10 | 2024-03 | -1.15 | N/A | N/A | N/A |
| 2024-05-10 | 2024-03 | -1.15 | -0.73 | 0.42 | 36.52% |
| 2024-03-22 | 2023-12 | -1.13 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-06-27 | WARBINGTON TIMOTHY | Chief Executive Officer | 34.90K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Aaron Wealth Advisors | 19.57K | 42.47K | 1.12% |
| 2024-09-29 | Vanguard Group Inc | 17.63K | 38.25K | 1.01% |
| 2024-09-29 | Two Sigma Advisers, LP | 14.50K | 31.47K | 0.83% |
| 2024-09-29 | Two Sigma Investments, LP | 13.11K | 28.44K | 0.75% |
| 2024-09-29 | UBS Group AG | 2.73K | 5.91K | 0.16% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 1.40K | 3.04K | 0.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 17.63K | 38.25K | 1.01% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 7.11K | 15.42K | 0.41% |
| 2024-10-30 | Fidelity Total Market Index Fund | 1.55K | 3.37K | 0.09% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 1.44K | 3.13K | 0.08% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2023-06-12 |
| 1 : 500 | 2021-11-10 |
| 1 : 150 | 2020-02-03 |